Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01099228 · ClinicalTrials.gov registry record · NA
Combination Targeted Radiotherapy in Neuroendocrine Tumors
A NA study, sponsored by David Bushnell.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT01099228 is a NA study that has completed, run by David Bushnell. The registered enrollment target is 2 participants.
The verdict
NCT01099228, a NA study, has completed, sponsored by David Bushnell.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary aim of this project is to determine, what fraction of individuals with neuroendocrine tumors would show substantially improved tumor dosimetry with combined agent therapy compared to "best" single agent therapy and determine the magnitude of the potential tumor radiation dose increase.
Interventions
- OTHER 131-I MIBG and 111-In pentetreotide
- OTHER 131-I MIBG and In-111 DOTATATE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-09 |
| Est. Completion | 2015-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01099228
The ClinicalTrials.gov registry entry for NCT01099228 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Bushnell, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 131-I MIBG and 111-In pentetreotide is the first listed.
NCT01099228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01099228 about?
NCT01099228 is a clinical study titled "Combination Targeted Radiotherapy in Neuroendocrine Tumors". The primary aim of this project is to determine, what fraction of individuals with neuroendocrine tumors would show substantially improved tumor dosimetry with combined agent therapy compared to "best" single agent therapy and determine the magnitude of the potential tumor radiation dose increase.
What is the current status of trial NCT01099228?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2006-09. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01099228?
The interventions under investigation include: 131-I MIBG and 111-In pentetreotide (OTHER), 131-I MIBG and In-111 DOTATATE (OTHER).
Who is sponsoring clinical trial NCT01099228?
This trial is sponsored by David Bushnell, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.